Jin Medical (ZJYL) appoints Enrome LLP as new independent auditor
Rhea-AI Filing Summary
Jin Medical International Ltd. changed its independent auditor, dismissing Audit Alliance LLP effective June 2, 2026, following board approval. Audit Alliance had audited the company for the years ended September 30, 2024 and 2025 and issued no adverse opinions, disclaimers, or qualifications.
The company reports there were no disagreements with Audit Alliance on accounting principles, financial disclosure, or audit scope, and no reportable events under Item 304(a)(1)(v)(A)-(D) of Regulation S‑K. On June 2, 2026, Jin Medical engaged Enrome LLP as its new independent registered public accounting firm for the fiscal year ending September 30, 2026.
The company also notes it had not consulted Enrome LLP on accounting matters or audit opinions during the past two fiscal years before this engagement. This report is incorporated by reference into Jin Medical’s existing Form F-3 registration statement.
Positive
- None.
Negative
- None.
Key Figures
Dismissal date of former auditor: June 2, 2026
Engagement date of new auditor: June 2, 2026
Fiscal year audited by new firm: Year ending September 30, 2026
+2 more
5 metrics
Dismissal date of former auditor
June 2, 2026
Effective date Audit Alliance LLP was dismissed
Engagement date of new auditor
June 2, 2026
Date Enrome LLP was engaged
Fiscal year audited by new firm
Year ending September 30, 2026
Engagement scope for Enrome LLP
Years audited by Audit Alliance
Years ended September 30, 2024 and 2025
Prior audit coverage by former auditor
Registration statement referenced
Form F-3 File No. 333-288314
6-K incorporated by reference
Key Terms
independent registered public accounting firm, Regulation S-K, reportable events, foreign private issuer, +1 more
5 terms
independent registered public accounting firm financial
"dismissed its independent registered public accounting firm, Audit Alliance LLP"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
Regulation S-K regulatory
"None of the reportable events described under Item 304(a)(1)(v)(A)-(D) of Regulation S-K occurred"
A set of U.S. Securities and Exchange Commission rules that tell public companies which narrative and qualitative details must be disclosed in filings, such as risk factors, management discussion, executive pay, legal proceedings and business description. Think of it as a standardized checklist or blueprint that ensures investors get the same types of background information from every company so they can compare risks, management quality and strategy before making investment decisions.
reportable events regulatory
"None of the reportable events described under Item 304(a)(1)(v)(A)-(D) of Regulation S-K occurred"
Reportable events are significant incidents or changes a company is legally required to disclose to regulators and the public, such as major safety problems, legal actions, financial irregularities, or management changes. They matter to investors because these events can alter a company’s risk profile or future performance, much like a dashboard warning light signals a problem that could affect a car’s safety or reliability. Timely disclosure helps investors make informed decisions and maintain market fairness.
foreign private issuer regulatory
"REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"
A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.
registration statement on Form F-3 regulatory
"deemed to be incorporated by reference into the registration statement on Form F-3"
A registration statement on Form F-3 is a streamlined filing used by eligible foreign companies to register securities for sale in the U.S., often as a “shelf” that lets them offer shares quickly when market conditions are right. For investors it matters because it signals that the company can raise capital on short notice—potentially increasing liquidity but also the risk of share dilution if new stock is issued—similar to a company keeping a pre-approved credit line ready to use.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What auditor change did Jin Medical International Ltd. (ZJYL) announce?
Jin Medical dismissed Audit Alliance LLP as its independent auditor effective June 2, 2026. The board approved the change, and Enrome LLP was engaged to audit the fiscal year ending September 30, 2026, replacing Audit Alliance going forward.
Did Jin Medical (ZJYL) report any disagreements with its former auditor?
The company states it had no disagreements with Audit Alliance LLP on accounting principles, financial statement disclosure, or audit scope. It also reports no reportable events under Item 304(a)(1)(v)(A)-(D) of Regulation S-K during the engagement period.
Who is Jin Medical’s new independent auditor for fiscal 2026?
Jin Medical engaged Enrome LLP on June 2, 2026 as its new independent registered public accounting firm. Enrome will audit the company’s financial statements for the fiscal year ending September 30, 2026, succeeding Audit Alliance LLP in this role.
Did Jin Medical (ZJYL) consult Enrome LLP before hiring it as auditor?
The company reports it did not consult Enrome LLP in the past two fiscal years on applying accounting principles, specific transactions, or likely audit opinions. This aligns with SEC disclosure rules for auditor changes under Regulation S-K Item 304(a)(2).
How does this 6-K affect Jin Medical’s Form F-3 registration statement?
The 6-K is incorporated by reference into Jin Medical’s existing Form F-3 registration statement. This means the disclosed auditor change and related details become part of the registration statement’s public record for securities offering purposes.